



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
Main Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2016

---

## Flagging Drugs That Inhibit the Bile Salt Export Pump

Montanari, Floriane ; Pinto, Marta ; Khunweeraphong, Narakorn ; Wlcek, Katrin ; Sohail, M Imran ;  
Noeske, Tobias ; Boyer, Scott ; Chiba, Peter ; Stieger, Bruno ; Kuchler, Karl ; Ecker, Gerhard F

**Abstract:** The bile salt export pump (BSEP) is an ABC-transporter expressed at the canalicular membrane of hepatocytes. Its physiological role is to expel bile salts into the canaliculi from where they drain into the bile duct. Inhibition of this transporter may lead to intrahepatic cholestasis. Predictive computational models of BSEP inhibition may allow for fast identification of potentially harmful compounds in large databases. This article presents a predictive in silico model based on physicochemical descriptors that is able to flag compounds as potential BSEP inhibitors. This model was built using a training set of 670 compounds with available BSEP inhibition potencies. It successfully predicted BSEP inhibition for two independent test sets and was in a further step used for a virtual screening experiment. After in vitro testing of selected candidates, a marketed drug, bromocriptin, was identified for the first time as BSEP inhibitor. This demonstrates the usefulness of the model to identify new BSEP inhibitors and therefore potential cholestasis perpetrators.

DOI: <https://doi.org/10.1021/acs.molpharmaceut.5b00594>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-118806>

Journal Article

Accepted Version

Originally published at:

Montanari, Floriane; Pinto, Marta; Khunweeraphong, Narakorn; Wlcek, Katrin; Sohail, M Imran; Noeske, Tobias; Boyer, Scott; Chiba, Peter; Stieger, Bruno; Kuchler, Karl; Ecker, Gerhard F (2016). Flagging Drugs That Inhibit the Bile Salt Export Pump. *Molecular Pharmaceutics*, 13(1):163-171.

DOI: <https://doi.org/10.1021/acs.molpharmaceut.5b00594>

## Flagging drugs that inhibit the bile salt export pump

Floriane Montanari, Marta Pinto, Narakorn Khunweeraphong, Katrin Wlcek, M. Imran Sohail, Tobias Noeske, Scott Boyer, Peter Chiba, Bruno Stieger, Karl Kuchler, and Gerhard F. Ecker

*Mol. Pharmaceutics*, **Just Accepted Manuscript** • DOI: 10.1021/acs.molpharmaceut.5b00594 • Publication Date (Web): 07 Dec 2015

Downloaded from <http://pubs.acs.org> on December 11, 2015

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



## Flagging drugs that inhibit the bile salt export pump

Floriane Montanari<sup>§,1</sup>, Marta Pinto<sup>§,1</sup>, Narakorn Khunweeraphong<sup>§,2</sup>, Katrin Wlcek<sup>1</sup>, M. Imran Sohail<sup>4</sup>, Tobias Noeske<sup>3</sup>, Scott Boyer<sup>¥,3</sup>, Peter Chiba<sup>4</sup>, Bruno Stieger<sup>5</sup>, Karl Kuchler<sup>2</sup>, Gerhard F. Ecker<sup>1,\*</sup>

<sup>§</sup>*these authors contributed equally to the work*

<sup>1</sup>University of Vienna, Department of Pharmaceutical Chemistry, Althanstrasse 14, 1090 Vienna, Austria

<sup>2</sup>Medical University of Vienna, Max F. Perutz Laboratories, Vienna Biocenter, Vienna, Austria

<sup>3</sup>Drug Safety and Metabolism, AstraZeneca R&D Mölndal, Pepparedsleden 1, Mölndal 43183, Sweden

<sup>4</sup>Institute of Medical Chemistry, Medical University of Vienna, Waehringerstrasse 10, Vienna, Austria

<sup>5</sup>Department of Clinical Pharmacology and Toxicology, University Hospital, Zurich, Switzerland

<sup>¥</sup> Current address:

Swedish Toxicology Sciences Research Center, Södertälje, Sweden

---


\* send correspondence to:

gerhard.f.ecker@univie.ac.at

University of Vienna, Department of Pharmaceutical Chemistry, Althanstraße 14, 1090, Vienna, Austria

Tel. +431427755110

## Table of contents



## Abstract

The bile salt export pump (BSEP) is an ABC-transporter expressed at the canalicular membrane of hepatocytes. Its physiological role is to expel bile salts into the canaliculi from where they drain into the bile duct. Inhibition of this transporter may lead to intrahepatic cholestasis. Predictive computational models of BSEP inhibition may allow for fast identification of potentially harmful compounds in large databases.

This article presents a predictive *in silico* model based on physico-chemical descriptors that is able to flag compounds as potential BSEP inhibitors. This model was built using a training set of 670 compounds with available BSEP inhibition potencies. It successfully predicted BSEP inhibition for two independent test sets and was in a further step used for a virtual screening experiment. After *in vitro* testing of selected candidates, a marketed drug, bromocriptin, was identified for the first time as BSEP inhibitor. This demonstrates the usefulness of the model to identify new BSEP inhibitors, and therefore potential cholestasis perpetrators.

## Keywords

BSEP, classification model, inhibition, drug-induced cholestasis, bromocriptin

## Introduction

The bile salt export pump (BSEP; gene name *ABCB11*) is a member of the subfamily B of ABC transporters. It is expressed in the liver at the canalicular membrane of the hepatocytes. It transports bile salts from the hepatocytes into the bile using the energy provided by ATP hydrolysis. The main substrates of BSEP are monovalent conjugated bile acids such as taurochenodeoxycholate<sup>1</sup>. However, drugs such as pravastatin have also been shown to be transported by BSEP (although with low affinity and therefore without *in vivo* impact)<sup>2</sup>.

Impairment of BSEP expression or function due to mutations in the *ABCB11* gene leads to progressive familial intrahepatic cholestasis type 2 (PFIC2)<sup>3</sup>. PFIC2 is an autosomal recessive condition which starts at early childhood with mild cholestasis, but develops in more critical liver failures and may necessitate liver transplantation at later stages.

Inhibition of BSEP by small molecules may also impair its function. As a result, efflux of bile salts decreases, leading to their accumulation inside the hepatocytes and, consequently, to drug-induced liver injury (DILI) manifested as acquired intrahepatic cholestasis. Bosentan<sup>4</sup> and troglitazone<sup>5</sup> are two examples of drugs whose hepatotoxicity can be directly linked to an inhibition of BSEP. The latter was withdrawn from the market in 2000 for its toxicity.

While the Food and Drugs Administration (FDA) does not provide directives regarding the testing of drugs for their inhibitory activity on BSEP, the European Medicine Agency (EMA) suggests investigating potential inhibition of the transporter<sup>6,7</sup>. In case *in vitro* studies reveal an inhibition, the serum bile salt levels should be monitored *in vivo* during later phases in the drug development process. In this scenario, a fast and inexpensive *in silico* pre-screening of candidates could be useful in order to reduce the amount of *in vitro* tests needed.

1  
2  
3 There are few *in silico* models of BSEP inhibition available so far. The model of Hirano  
4 and colleagues<sup>8</sup> is based on a very small data set of 37 compounds and thus would not allow  
5 *in silico* profiling of chemically diverse compound libraries. Warner *et al.*<sup>9</sup> used a balanced  
6 training set of 437 compounds to build several classification models based on in-house  
7 descriptor sets, comprising 2D, 3D and fingerprint-like features. Their best model reached an  
8 accuracy of 0.87 (on a test set of 187 compounds). Finally, Pedersen and colleagues<sup>10</sup> built  
9 two orthogonal partial least-squares discriminant analysis (OPLS-DA) models on 163  
10 compounds. They report an accuracy of 0.89 on a test set of randomly selected 86  
11 compounds. However, none of these models were used in any prospective studies to  
12 identify new BSEP inhibitors and thereby demonstrate their performance in real life settings.  
13

14  
15 In this study, we built a classification model based on a set of physico-chemical  
16 descriptors for predicting BSEP inhibition. The model revealed the importance of  
17 hydrophobicity, aromaticity and H-bond donor characteristics for separating inhibitors from  
18 non-inhibitors. It had an accuracy of 84% in ten-fold cross-validation, 80% in a randomly  
19 selected external set, and 88% in a validation set built on publicly available data. A  
20 subsequent screen of the DrugBank database revealed many drugs already known as BSEP  
21 inhibitors in the top-ranked positions. To further evaluate the prospective usefulness of the  
22 model, we selected compounds from the top-scoring ones for which up to now no BSEP  
23 inhibition information was available. Selection criteria comprised, among others: chemical  
24 diversity, known bile elimination or liver metabolism, and commercial availability. Finally,  
25 seven compounds were experimentally tested using two distinct *in vitro* systems: a  
26 membrane vesicle assay and a more complex Transwell<sup>®</sup> assay. This led us to identify  
27 bromocriptin, a currently marketed drug, as BSEP inhibitor. The model has been  
28 implemented as a KNIME workflow<sup>12</sup> which is available for download from the  
29 supplementary material.  
30  
31  
32  
33  
34

## 35 Material and methods

36  
37 The original data was donated by AstraZeneca within the framework of the IMI project eTOX  
38 (www.etoxproject.eu). It contained the BSEP inhibitory potencies reported as IC<sub>50</sub> (μM)  
39 values of 1092 compounds provided as smile strings. Data was measured in a [<sup>3</sup>H]-  
40 taurocholate transport assay performed in Sf21 membrane vesicles following the protocol in  
41 13.  
42  
43

### 44 Database curation

45 The initial dataset was curated using the procedure described in Pinto *et al.*<sup>14</sup>. Briefly, it  
46 consists of the following steps: (1) removal of inorganic compounds (*i.e.* compounds not  
47 containing carbon atoms) using Instant JChem v.5.3, 2010, ChemAxon  
48 (<http://www.chemaxon.com>); (2) analysis and removal of mixtures formed by two or more  
49 large molecules; (3) deletion of organometallic compounds using MOE 2011.10<sup>15</sup>; (4)  
50 identification and removal of compounds containing special atoms such as selenium or  
51 tellurium by means of an in-house MOE SVL script; (5) normalization of chemotypes using  
52 the ChemAxon's Standardizer with the following settings: clean 2D, aromatize, mesomerize,  
53 neutralize, tautomerize and all transform options; (6) identification and elimination of non-  
54 unique structures using MOE; (7) deletion of compounds having permanent charges. The  
55 application of this procedure led to a curated data set of 1048 compounds.  
56  
57  
58  
59  
60

### Compound labeling

Compounds having an  $IC_{50}$  lower or equal to 10  $\mu M$  were considered as inhibitors, whereas those having an  $IC_{50}$  higher than 50  $\mu M$  were labeled as non-inhibitors. Compounds having activity values between 10 and 50  $\mu M$  were not considered to build the classification models and were discarded. This procedure led to a final data set formed by 838 compounds, 563 of which were non-inhibitors and 275 were inhibitors.

### Descriptor calculation

78 interpretable 1D and 2D descriptors representing physico-chemical properties were calculated using MOE2011.10<sup>15</sup>. These descriptors were not selected based on information content or correlation with the dependent variable, but rather on their physico-chemical interpretability. The exact list of descriptors is available as supplementary information. Descriptors of the training set were Z-normalized using KNIME<sup>12</sup>. Computed means and standard deviations were then applied to the different test sets (see below).

### Training and test set selection

80% of each class was randomly selected for use as training set. The remaining compounds were considered as test set. The composition of the resulting sets is shown in Table 1.

	Total	Inhibitors	Non inhibitors
Complete dataset	838	275	563
Training set	670	220	450
Test set	168	55	113
External set	156	39	117

Table 1: Composition of the datasets in number of compounds

### External validation

In order to assess the prospective predictive power of the model, an external validation was carried out using a data set compiled from the literature<sup>8,16</sup>. Hirano *et al.*<sup>8</sup> tested 42 compounds among neurotransmitters, calcium channel blockers, potassium channel modulators, steroids, non-steroidal anti-inflammatory drugs, anticancer drugs, and others. The percentage of inhibition of BSEP at 100  $\mu M$  was measured (in comparison with a negative control without test drug). The highest inhibition was obtained for nifedipine (100% inhibition), prenylamine (77% inhibition), fendiline (80% inhibition) and nifedipine (75% inhibition) from the calcium channel blockers, while the other compounds showed low to moderate inhibition (under 50%). Those were therefore not considered as inhibitors.

Morgan *et al.*<sup>16</sup> measured the BSEP inhibition activity of 217 compounds to relate them with liver injuries. Compounds with  $IC_{50}$  below 25  $\mu M$  were taken as inhibitors, while compounds with  $IC_{50}$  over 135  $\mu M$  were taken as non-inhibitors. The 25  $\mu M$  threshold was chosen because, among the compounds that were present both in the training set and in<sup>16</sup>, the equivalent  $IC_{50}$  in the training set was usually below 10  $\mu M$ .

The chemical structures were retrieved by name from Pubchem Compound (<http://www.ncbi.nlm.nih.gov/pccompound>). This external set was curated using the same protocol as previously described. Those compounds also present in the AstraZeneca data set

1  
2  
3 were removed, leading to a final set formed by 156 compounds, 39 inhibitors and 117 non-  
4 inhibitors.

### 6 **Model building**

7 The Weka 3.7.10 library <sup>17</sup> was used to build a set of classification models. The machine  
8 learning algorithms Naïve Bayes (NB), k-nearest neighbor (IBk), J48 and Random Forest (RF)  
9 were used with embedded attribute selection (CfsSubsetEval evaluator and BestFirst search).  
10 Additionally, in order to improve the performance of the models, optimization of the  
11 number of neighbors in IBk, the minimum number of instances per leaf in J48 or the number  
12 of trees in RF was performed using the CVParameter selection tool provided by Weka with  
13 an internal 5-fold cross-validation.

14  
15  
16 The model showing best performance was implemented as a KNIME workflow <sup>12</sup>. It is  
17 available for download in the supplementary information. KNIME is an Open Software  
18 platform used for implementing pipeline-like workflows. Here, the pipeline starts by reading  
19 the input dataset (as an sd file), then computes the required descriptors using the MOE  
20 node. The trained model is then read and the new compounds passed through, and the  
21 predictions (both as a score between 0 and 1 and as a binary outcome) are saved in a csv  
22 file. All necessary information to install and use the model is available in the Supplementary  
23 Information. However, a MOE license is required to calculate all descriptors needed.

### 26 **Virtual screening**

27 A total number of 1700 compounds were retrieved from the DrugBank database  
28 ([www.drugbank.ca](http://www.drugbank.ca), <sup>18</sup>) (as of October 2013) and curated using the same protocol as that  
29 described in the Database curation section. These compounds were passed through the  
30 model and ranked according to their predicted inhibitor score, which roughly corresponds to  
31 their probability of inhibiting BSEP according to the model.

### 34 **Chemical similarity**

35 Chemical similarity was measured by Tanimoto similarity on RDKit fingerprints <sup>19</sup>.

### 38 ***In vitro* testing**

#### 39 Materials

40 [<sup>14</sup>C]-taurocholic acid and [<sup>3</sup>H]-taurocholic acid were purchased from American Radiolabeled  
41 Chemicals, Inc. (St. Louis, MO, USA). Taurocholic acid was obtained from ICN Biomed, Inc.  
42 (Irvine, California, USA). Cyclosporin A, pioglitazone, taurocholate, ATP, Mg(NO<sub>3</sub>)<sub>2</sub> and  
43 sodium butyrate were from Sigma (St. Louis, MO, USA). TRIS and Hepes were purchased  
44 from Roth (Karlsruhe, Germany), sucrose from neoLab (Heidelberg, Germany), and KNO<sub>3</sub> and  
45 KCl from Merck (Darmstadt, Germany). All other compounds were obtained from Glentham  
46 Life Sciences Ltd (Wimbleton, London, United Kingdom). LLC-PK1 stable cell lines expressing  
47 BSEP and NTCP were generated in the laboratory of B. Stieger. The expression analysis of  
48 BSEP was performed by western blot analysis and is available as Supplementary Information.  
49 CHO Flip-In cells expressing NTCP were characterized in <sup>20</sup>. The liquid scintillation fluid Filter  
50 Count, used in transport studies, was purchased from PerkinElmer (Waltham, MA, USA).

#### 54 Cell culture

55 LLC-PK1 cells stably expressing BSEP and NTCP were cultured in DMEM (Life Technologies,  
56 Rockville, MD, USA) supplemented with 10% fetal calf serum (FCS), 2 µg/mL puromycin and  
57  
58  
59  
60



700 µg/mL G418. Chinese hamster ovary (CHO) Flip-In cell lines were cultured in Ham's F-12 medium (Gibco-Thermo Fisher Scientific, Waltham, Massachusetts, USA) containing 100 IU/mL penicillin/streptomycin, 10% fetal calf serum, 1 mM l-glutamine. CHO WT cells were maintained in the presence of 0.1 mg/mL Zeocin (Invitrogen, Waltham, Massachusetts, USA) whereas CHO-NTCP cells were cultured with 0.5 mg/mL hygromycin B (Invitrogen, Waltham, Massachusetts, USA). All cells were cultured at 37°C in an atmosphere containing 5% CO<sub>2</sub> with 95% relative humidity.

#### Taurocholate transport studies in BSEP-expressing Hi5 membrane vesicles

ATP-dependent uptake of [<sup>3</sup>H]-taurocholate by BSEP was measured using human BSEP-expressing Hi5 membrane vesicles (Solvo, Budapest, Hungary) and the rapid filtration technique as previously described<sup>20</sup>. Vesicles were diluted to a concentration of 2.5 µg/µL with 50 mM sucrose, 100 mM KNO<sub>3</sub>, 20 mM HEPES/Tris pH 7.4; 10 µL of vesicles was pre-warmed in a 37°C water bath for 30 sec, and uptake was initiated by the addition of 40 µL uptake buffer (50 mM sucrose, 100 mM KNO<sub>3</sub>, 12.5 mM Mg(NO<sub>3</sub>)<sub>2</sub>, 10 mM HEPES/Tris, pH 7.4) containing radiolabelled taurocholate (3 µCi/mL; final concentration in the assay 2.5 µM). After 10 min of incubation in the 37°C water bath, transport was stopped by adding 3 mL of ice-cold stop solution (50 mM sucrose, 100 mM KCl, 10 mM Tris/HCl, pH 7.4) and immediate filtration through 0.45 µm nitrocellulose acetate filter (Sartorius, Göttingen, Germany) pre-soaked with 1 mM taurocholate solution. The tube was rinsed once with 3 mL of cold stop solution and also filtered. After filter washing with 3 mL of ice-cold stop solution twice, the filter was dissolved in liquid scintillation fluid and radioactivity was measured in a Beckman Counter. For inhibition studies, the compounds were added to the uptake buffer to reach a final concentration of 10 µM. The final DMSO concentration in all samples was 0.8%. As recommended by the manufacturer, cyclosporin A was used as positive control at a final concentration of 20 µM. In addition, pioglitazone was used as positive control at a final concentration of 10 µM. To measure ATP-dependent taurocholate (TC) uptake, 5 mM ATP (final concentration in the assay) was added to the uptake buffer, and uptake rates were calculated as the difference in uptake in the presence and in the absence of ATP. Hi5-beta galactosidase membrane vesicles (Solvo, Budapest, Hungary) were used as negative control to measure endogenous TC transport of Hi5 membrane vesicles.

#### IC<sub>50</sub> determination of bromocriptin in BSEP-expressing Hi5 membrane vesicles

ATP-dependent uptake of [<sup>3</sup>H]-taurocholate by BSEP was measured in absence and presence of 8 different concentrations of bromocriptin at an incubation time of 5 min as described in the section above. For IC<sub>50</sub> measurements of bromocriptin, stock solutions were prepared by a 1:2.5 serial dilution in DMSO, resulting in final bromocriptin concentrations ranging from 50 to 0.08 µM. Final DMSO concentration in all samples was 0.8 %. The uptake rates, calculated as the difference in uptake in the presence and in the absence of ATP, were plotted against the logarithmic concentration of bromocriptin in µM. IC<sub>50</sub> values were calculated by nonlinear regression analysis using GraphPad Software Inc. (San Diego, CA, USA) Prism version 6.00 and the equation

$$y = y_{min} + \frac{(y_{max} - y_{min})}{1 + 10^{(\log IC_{50} - x) \cdot a}}$$

where *a* is the Hill Slope.

#### Taurocholate transport studies in LLC-PK1 NTCP- and BSEP-expressing cells

The transcellular assay was set up following the methodology reported in Kagawa *et al.*<sup>21</sup> with some modifications. Briefly, LLC-PK1 stable cell line expressing BSEP and NTCP were plated on a Transwell® membrane insert (no. 3470, diameter 6.5 mm, pore size 0.4 µm, Corning Costar, Cambridge, MA, USA) at a concentration of  $2 \times 10^5$  cells/membrane. After 24 h, the cells were treated with 5 mM sodium butyrate for further 24 h. To measure taurocholic acid transport activity, cells were washed twice with PBS and moved to DMEM (without FCS or antibiotic). Subsequently, the cells were incubated with pre-warmed basal medium containing 10 µM [<sup>14</sup>C]-taurocholic acid and pre-warmed apical compartment in the presence or absence of test compounds. After 1 h incubation under humidified condition at 37°C with 5% CO<sub>2</sub>, the apical medium was collected for measurement of the radioactivity using a scintillation counter (Tri-Carb 2100TR, PerkinElmer).

#### Taurocholate transport studies in CHO NTCP-expressing cells

[<sup>14</sup>C]-Taurocholic acid uptake and inhibition of NTCP were performed in CHO-WT and CHO Flip-In NTCP cells as described previously<sup>22</sup>. Cells were plated at the density of  $1 \times 10^5$  cells/well onto 24-well plates. Twenty-four hours after seeding, the cells were treated with 5 mM sodium butyrate and cell culture was pursued for further 24 h prior to the experiment. Before the uptake experiment, CHO cells were rinsed three times with 1 mL of pre-warmed uptake buffer and then pre-incubated in 500 µL of pre-warmed buffer before adding substrate. To measure Na-driven NTCP-mediated transport, two different uptake buffers were used either with sodium (116.4 mM NaCl, 5.3 mM KCl, 1 mM NaH<sub>2</sub>PO<sub>4</sub>, 0.8 mM MgSO<sub>4</sub>, 5.5 mM D-glucose, and 20 mM HEPES/Tris pH 7.4) or without (116.4 mM choline chloride, 5.3 mM KCl, 1 mM KH<sub>2</sub>PO<sub>4</sub>, 0.8 mM MgSO<sub>4</sub>, 5.5 mM D-glucose, and 20 mM HEPES/Tris pH 7.4). Taurocholic acid uptake was initiated by the addition of 500 µL pre-warmed uptake buffer containing 2.5 µM taurocholic acid (0.025 µCi/mL [<sup>14</sup>C]-taurocholic acid). After 5 min of incubation at 37° C, the uptake was stopped by removal of the uptake solution followed by washing 3 times with 1 mL ice-cold uptake buffer. The cells were then lysed in 500 µL of 0.1 mM NaOH for at least 1 h at room temperature. The lysate suspension was used for radioactivity measurement by liquid scintillation counting. For the inhibition studies, the uptake was examined in the presence of positive control (cyclosporin A) or test compounds at a final concentration 10 µM. DMSO was adjusted to 1% as a control in all experiments.

#### Statistical analysis

Statistical analyses were performed by using unpaired, parametric t-test using GraphPad Software Inc. (San Diego, CA, USA) Prism version 6.00. Data were normalized to DMSO control, which was set as 100%. T-test was applied to compare each single compound with the DMSO control.

## Results

### Classification model

As outlined in the methods section, a panel of classifiers was trained on a set of 670 compounds in order to predict if a compound acts as BSEP inhibitor. The performance of the

best model, a Random Forest of 10 trees with integrated feature selection based on a set of 78 1D and 2D descriptors, is reported in Table 2. A charged and a neutralized version of the training set were used and the neutralized version gave the best cross-validation results.

	TN	FN	TP	FP	MCC	ROC area
10-fold CV	408	65	155	42	0.63	0.91
5-fold CV	409	68	152	41	0.62	0.91
Test set	97	18	37	16	0.54	0.87
External set	108	9	30	9	0.69	0.92

Table 2: Confusion matrix, Matthews correlation coefficient and area under the ROC curve for the cross-validation and test sets for the best model.

On the basis of the features selected by the model (number of aromatic atoms (a\_aro), number of triple bonds (b\_triple), Van der Waals surface area of H bond donors (vsa\_don), number of Br atoms (a\_nBr), logP (logP(o/w)), Van der Waals surface area of hydrophobic atoms (vsa\_hyd), number of C atoms (a\_nC), number of rings (rings), molecular weight (weight)), hydrophobicity, the size of the molecule, the aromaticity and the number of hydrogen bond donors seem to play a critical role in BSEP inhibition.

### Virtual screening

Given the good performance of the model in internal and external validation, DrugBank was screened for potential BSEP inhibitors. For this, 1700 small molecules from the DrugBank database<sup>18</sup> were passed through the Random Forest and ranked by prediction score. This score takes values between 0 and 1, and the higher the score, the higher the probability of the compound to be a BSEP inhibitor according to the model. 59 compounds actually got the highest possible score, and were further investigated. Among them, 13 compounds were labeled as inhibitors in the training set used to build the model. 10 others were reported in the literature or in DrugBank as inhibitors of BSEP but were not part of the training set. Irinotecan and atorvastatin were reported as non-inhibitor and inhibitor at 50  $\mu$ M, respectively<sup>10</sup>. Since we used a threshold of 10  $\mu$ M to define an active in the training set, we count both results as false positives. Tamoxifen and nelfinavir are inconsistently reported with both inhibitor and non-inhibitor activities<sup>8,16,10,13</sup>. This leaves us with 32 compounds that are top ranked and for which we could not find any pharmacological annotation regarding BSEP.

A further analysis of the results of the screening for scores down to 0.8 (still predicted as inhibitors, but with less probability) retrieved 26 compounds with known BSEP annotation: 8 compounds that were present in the training set, 12 true positive (*i.e.* compounds found in literature to be inhibitors), 4 compounds with middle range activities and 2 false positive (*i.e.* compounds found in the literature to be non-inhibitors of BSEP). On the other hand, 1340 DrugBank small molecules received a score below 0.5, which is the threshold used for binary prediction. This means that the model predicts those compounds as non-inhibitors of BSEP. We studied these compounds and found 314 for which there was a pharmacological annotation available. 147 of them were actually part of the training set of the model (including 2 misclassified compounds), while 161 compounds were reported in the literature as non-inhibitors but were not part of the training set. Another 18 compounds had IC<sub>50</sub> values over 10  $\mu$ M but below 50  $\mu$ M, and as such do not strictly count as errors

1  
2  
3 since we used 10  $\mu\text{M}$  as a threshold to define the inhibitors in the training set. Finally, six  
4 compounds were mispredicted as non-inhibitors while they were actually reported as  
5 inhibitors: atazanavir<sup>10,23</sup>, telithromycin<sup>8,16</sup>, ranolazine<sup>10</sup>, trovafloxacin<sup>23</sup>, pioglitazone<sup>13,9,16</sup>  
6 and diethylstilbestrol<sup>10</sup>. This results in 161 true negatives and 6 false negatives, which  
7 corresponds to a negative predictive value of 96% (the negative predictive value is obtained  
8 by dividing the number of true negatives by the total number of predicted negatives). To  
9 compare with, the negative predictive value obtained for the 10-fold cross-validation was  
10 86%, 84% for the randomly selected test set and 92% for the external set. The positive  
11 predictive value for the top scoring compounds analyzed here is 0.73 (22 true positives and 8  
12 false positives). This value is lower than the one obtained for the external set (0.77), the 10-  
13 fold cross-validation (0.79) but higher than the one of the randomly selected test set (0.70).  
14  
15

### 16 17 ***In vitro* testing**

18 Among the 32 compounds which received the highest score in the model and had no  
19 reported BSEP interaction in the literature, we eliminated one compound, halobetasol,  
20 which has topical application. Fourteen compounds that were not reported to undergo liver  
21 metabolism or elimination were removed. To ensure that compounds do not have a  
22 Tanimoto similarity > 0.75 to any other compound within the set or in the training set, we  
23 removed toremifene, which had a similarity of 0.94 with one compound of the training set.  
24 This led to a short list of 16 compounds, whereby 7 of them could finally be purchased.  
25

26 To directly assess BSEP inhibition, we used a membrane vesicle assay as  
27 recommended by the International Transporters Consortium<sup>24</sup>. This kind of assay has the  
28 advantage of showing the direct impact of the test compounds on BSEP-mediated  
29 taurocholate (TC) transport. It is devoid of metabolism or permeability uptake problems.  
30

31 The obtained results at a single concentration of test compounds are reported in  
32 Figure 1. In addition to the positive controls cyclosporin A and pioglitazone, which indeed  
33 decreased TC uptake to  $15 \pm 3\%$  and  $8 \pm 3\%$  respectively, bromocriptin reduced BSEP-  
34 mediated TC uptake significantly to  $45 \pm 10\%$ . In contrast, raloxifen and vecuronium  
35 increased BSEP-mediated TC transport significantly to  $125 \pm 7\%$  and  $114 \pm 7\%$ , respectively,  
36 as compared to the DMSO control. All other compounds did not affect BSEP function.  
37 Vesicles which did not express BSEP were used as negative control to exclude TC transport  
38 by endogenously expressed transporters in Hi5 cells. Indeed, these vesicles showed only  $3 \pm$   
39  $1\%$  of TC transport compared to vesicles expressing BSEP.  
40

41 The inhibitory activity of bromocriptin was studied in more detail by an  $\text{IC}_{50}$  value  
42 determination. As shown in Figure 2, an  $\text{IC}_{50}$  value of  $1.2 \pm 0.1 \mu\text{M}$  was evaluated.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1: Effect of different compounds on BSEP-mediated TC transport. ATP-dependent uptake of 2.5  $\mu$ M TC in BSEP-Hi5 membrane vesicles was measured in absence (black bar) and presence of the test compounds (light grey) or known BSEP inhibitors (dark grey) as described in the materials and methods section. TC uptake data are given as the mean percentage of DMSO control  $\pm$  SD of 3 independent experiments. Each experiment was performed in technical triplicates. Compounds showing significant different TC uptake as compared to DMSO control are marked with asterisks (\*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*\* $p < 0.0001$ ).




Figure 2: Effect of bromocriptin on BSEP-mediated TC transport. ATP-dependent uptake of 2.5  $\mu$ M TC in BSEP-Hi5 membrane vesicles was measured in absence and presence of eight increasing concentrations of bromocriptin as described in the Materials and Methods section. Data are given as the mean percentage of TC uptake compared to the DMSO control  $\pm$  SD of 3 independent experiments. Each experiment was performed in technical triplicates.

In an attempt to evaluate BSEP inhibition in a whole-cell system, we also tested the seven compounds in a transcellular flux assay. For this, we used LLC-PK1 cells expressing NTCP at the basolateral and BSEP at the apical membrane (see Supplementary Information, Figure SI-3). NTCP mediates the uptake of taurocholate from the basal compartment, while BSEP exports taurocholate into the apical medium. The final amount of transported substrate is measured from the apical compartment. The inhibition results at a single concentration (10  $\mu$ M) of test compounds are shown in Figure 3. The positive controls, cyclosporin A and pioglitazone, showed lower taurocholate transport ( $42 \pm 11\%$  and  $55 \pm$

18%, respectively). Bromocriptin was found again to cause a decreased transport of taurocholic acid ( $69 \pm 5\%$ ). In addition, montelukast showed an inhibitory effect ( $57 \pm 18\%$ ).




Figure 3: BSEP inhibition study in a transcellular flux assay. Effect of known BSEP inhibitors (cyclosporin A and pioglitazone, dark grey bars) and test compounds (light grey) was studied using LLC-PK1 cells stably expressing BSEP and NTCP in a Transwell® system as described in the Materials and Methods section. Data show the amount of taurocholate in the apical compartment medium as a percentage of the DMSO control (absence of compound). Data are given as the mean percentage of taurocholate uptake compared to the DMSO control (black bar)  $\pm$  SD of at least 3 independent experiments. Compounds showing significant different TC amount in the apical compartment as compared to DMSO control are marked with asterisks (\*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ).

As previously described, the transcellular transport of taurocholate (TC) through a cell monolayer is mediated by the sodium-dependent TC uptake transporter NTCP at the basolateral side and the ATP-dependent TC efflux via BSEP at the apical side. As montelukast showed no inhibitory effect on BSEP in the vesicle assay, but showed inhibition of the transcellular flux of TC, we investigated the effect of the known NTCP inhibitor cyclosporin A as well as bromocriptin and montelukast on NTCP-mediated TC transport. Cyclosporin A shows a strong inhibition at  $10 \mu\text{M}$  ( $13 \pm 1\%$ ). Interestingly, montelukast also inhibits taurocholic acid uptake by NTCP ( $46 \pm 7\%$ ), while bromocriptin shows no significant effect compared to the DMSO control (see Supplementary Information, Figure SI-4).

## Discussion

After pharmacokinetics problems and lack of efficacy, the toxicity of compounds is a major cause of failures in late stages of drug development<sup>25</sup>. In particular, DILI is the most frequent reason for withdrawal of approved drugs<sup>26</sup>. Early identification of such problematic compounds must be a priority for obvious economic and social reasons.

BSEP inhibition has been correlated with drug-induced liver injury (DILI)<sup>13</sup>. As bile salt transporter localized at the canalicular membrane of hepatocytes, BSEP is the major

1  
2  
3 constituent to generate bile flow, mediating the transport of monovalent bile salts into bile  
4 <sup>27</sup>. Any impairment of BSEP function results in bile acid accumulation and consequently liver  
5 injury due to the bile acid cytotoxicity <sup>28,29,30,31,32,33,34,35</sup>. Dawson and colleagues <sup>13</sup> studied  
6 the relationship between drug-induced hepatotoxicity and the potency of BSEP inhibition for  
7 85 pharmaceuticals. They found out that all the 17 drugs in their dataset having an IC<sub>50</sub> for  
8 human BSEP inhibition below 100 μM caused DILI. They also found that BSEP inhibitors tend  
9 to have high molecular weight and lipophilicity. Similar correlation was found by Pedersen  
10 and colleagues <sup>10</sup>, where more than half of the BSEP inhibitors in their study were strong DILI  
11 inducers.  
12

13  
14 To the best of our knowledge, three ligand-based models to predict BSEP inhibition  
15 have been reported so far <sup>8,9,10</sup>. Briefly, Hirano and colleagues fitted a QSAR model to predict  
16 the percentage of inhibition by linear regression on 37 compounds <sup>8</sup>. They report a R<sup>2</sup> of 0.95  
17 but did not perform a cross-validation to evaluate the predictivity of their model. More  
18 recently, Warner and colleagues used a larger dataset (437 compounds) to build a binary  
19 classification model to predict BSEP inhibition. The best external validation performance was  
20 obtained with support vector machine built on in-house descriptors (accuracy: 0.87,  
21 sensitivity: 0.9, specificity: 0.84) <sup>9</sup>. Finally, Pedersen and colleagues performed partial least-  
22 square discriminant analysis to classify BSEP strong inhibitors, weak inhibitors and non-  
23 inhibitors <sup>10</sup>. The best model was obtained when using only the two classes “strong  
24 inhibitors” versus “non-inhibitors”. In that case, the training set contained 142 compounds  
25 and the test set 74 compounds (accuracy: 0.89, sensitivity: 0.76, specificity: 0.94).  
26  
27

28 Our own models were built on a significantly larger training set (670 compounds) and  
29 validated by cross-validation and external sets. The external validation gives an accuracy of  
30 0.88, sensitivity of 0.77 and a specificity of 0.92 (Table 2). This is equivalent to the values  
31 reported in <sup>9,10</sup>. The high area under the ROC curve (AUC, around 0.9 for all validation  
32 schemes) shows a great capacity for our model at ranking compounds by their probability of  
33 being inhibitors of BSEP. The AUC is a good metrics for virtual screening applications and  
34 present the advantage of being independent from class distributions <sup>11,36</sup>.  
35

36 The model is extremely fast (the longest step being the computation of the molecular  
37 descriptors) and can be used on a large number of compounds in a timely manner. As a  
38 reference, we needed around 2 min in a regular desktop computer to predict the 1700  
39 DrugBank compounds. The implementation into a KNIME workflow allows pipelining the  
40 whole process, so that there is no need to load the whole library of compounds in the  
41 memory. Instead, the molecules to predict are treated one by one, which allows to process  
42 libraries of any size.  
43

44 Such *in silico* models, because of their ability to treat millions of compounds in a  
45 timely manner, could in theory be used to pre-filter large libraries of compounds. There are,  
46 however, a certain number of pitfalls that should be noted. First, models, even the best  
47 ones, make mistakes. That means that one can filter out compounds that actually would not  
48 have caused any BSEP inhibition. Or, on the contrary, compounds with bad BSEP profiles  
49 might sneak in the filtered database. In this sense, *in silico* models won't replace *in vitro*  
50 testing, they rather aid in prioritizing compounds for being tested or not. Second, ligand-  
51 based models depend on their training set. The larger, more diverse the training set is, the  
52 more likely it is that the model will perform well on a set of new compounds. It is common  
53 practice in the industry to regularly update and retrain models. Indeed, as time passes, the  
54 chemical focus of a company may switch and lead to an increase of errors of an initially well-  
55 performing model. So retraining the model using an updated chemical space helps stabilizing  
56  
57  
58  
59  
60

1  
2  
3 the error rate of the models. Also, the quality of the pharmacological data behind the  
4 training set is crucial. If many different assays were used to generate this data, then a proper  
5 handling and assay-per-assay evaluation should be performed before even building a model  
6 <sup>37</sup>. Otherwise, noisy and even disagreeing data may be taken as training set and lead to poor  
7 models. In this study, we were in the ideal case where all data used to build the model came  
8 from a single assay, performed within the same company.  
9

10 In the absence of a crystal structure for BSEP, we lack knowledge on the interaction  
11 pattern by which drugs inhibit the transporter at the molecular level. The embedded feature  
12 selection reveals a set of descriptors related to hydrophobicity, size of the molecules, as well  
13 as number of H bond donors as critical for assigning inhibitor/non-inhibitor class labels. The  
14 latter seems contradictory to the results of Warner *et al.* <sup>9</sup>, who find similar tendencies  
15 regarding molecular weight and lipophilicity for the inhibitor set, but an opposite  
16 relationship for H bond donors: “... molecules with an increasing number of donors were at  
17 reduced risk of BSEP inhibition ( $p < 0.0001$ )”. This apparent discrepancy in our respective  
18 findings could be the result of the neutralization step applied to our compound structures  
19 before computing descriptors. Indeed, BSEP transports negatively charged compounds, and  
20 neutralization of such acids leads to strong H-bond donor features in the structure. There is  
21 no information in <sup>9</sup> regarding the pre-processing of chemical structures the authors may  
22 have applied. In this study, we tried both charged and uncharged versions of the training set  
23 to build the models, and it happened that the neutralized version gave higher cross-  
24 validation results.  
25  
26  
27

28 The model was used to prospectively screen DrugBank and proved a good recognition  
29 of already known inhibitors and non-inhibitors. In a later step, seven diverse compounds  
30 with unknown BSEP activity at the time of the screening were bought and tested *in vitro*.  
31 This led us to identify one new inhibitor of BSEP, while the six other compounds were false  
32 positives. These six compounds were chemically dissimilar from the training set (Table 3),  
33 which could explain the errors of the model. When taking together all the results from the  
34 DrugBank screen (including the top ranking compounds for which we did find BSEP inhibition  
35 in the literature), we obtain the following figures: 23 true positives (compounds that were  
36 identified either in the literature or in our assay as true positives), and 14 false positives  
37 (when taking a strict threshold at 10  $\mu$ M to define an active). This corresponds to a moderate  
38 positive predictive value of 0.62. While this can seem a high false alarm rate, one has to  
39 remember that it is the first time that an *in silico* model for BSEP has been actually used in  
40 such a prospective way. The usefulness of the model is actually to quickly sort out “safe”  
41 compounds (with high success, since we could find only 6 false negatives in the DrugBank  
42 screen) from potentially “troublesome” compounds. If one thinks of a safety assessment  
43 pre-screening, then it is actually quite desirable to have such a conservative model (*i.e.* a  
44 model with many false positives).  
45  
46  
47  
48

49

	Similarity to closest neighbor	Average similarity
Bromocriptin	0.75	0.44
Montelukast	0.51	0.35
Olmesartan	0.61	0.40
Pranlukast	0.60	0.36
Raloxifen	0.52	0.37
Vecuronium	0.56	0.41
Zafirlukast	0.56	0.40

50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Table 3: Tanimoto similarity between the seven tested compounds and the training set.

The vesicle assay identified bromocriptin as inhibitor of BSEP function. To the best of our knowledge, the effect of bromocriptin on BSEP function has not been investigated yet. Bromocriptin has been approved for the treatment of hyperprolactinemia syndromes, prolactinomas, acromegaly and Parkinson's disease in 1977. In 2009, bromocriptin mesylate was additionally approved for the treatment of type 2 diabetes<sup>38</sup>. Although we showed clear inhibitory effect on BSEP function, this drug is not known to cause cholestasis. According to the LiverTox database<sup>39</sup>, bromocriptin has been reported to trigger an asymptomatic elevation of serum aminotransferase levels. Only rare instances of acute liver injury have been reported and no case reports were published. Bromocriptin is therefore considered as a safe drug regarding liver injury. The absence of DILI may be due to extensive metabolism of bromocriptin, essentially by the cytochrome CYP3A subfamily<sup>40,41</sup>, which most likely leads to low intracellular concentration of bromocriptine in hepatocytes. In addition, unbound plasma concentrations of bromocriptin are about 60 times lower (15 nM,<sup>42</sup>) than the IC<sub>50</sub> of bromocriptin in the vesicle assay (1.2 μM).

Isolated membrane vesicles as well as the cell-based transcellular flux assay are common methods to study efflux transporters. We demonstrated inhibitory effects of cyclosporin A, pioglitazone and bromocriptin on BSEP function in both systems, even if this effect was more pronounced in isolated membrane vesicles. The observed difference in inhibition activity could be due to the fact that, in the inside-out vesicle assay, the test compound is directly applied to the interaction site of BSEP. On the other hand, in the transcellular assay, the exact amount of test compounds entering the cell and being available for interaction with BSEP is not known. Therefore, potential differences in concentrations at the active site may arise, leading to different inhibitory activities. Most probably, this variability between the two assays is not caused by the known difference in cholesterol content of insect and mammalian cell membranes. Indeed, although cholesterol does affect the transport kinetics of taurocholate by BSEP and the inhibitory activity of cyclosporine A, it does so by only affecting V<sub>max</sub> but not K<sub>m</sub> values<sup>43,44</sup>. The only controversial result found in membrane vesicle and cell-base inhibition studies was the effect of montelukast. While this compound had no effect on BSEP function in isolated membrane vesicles, an inhibitory activity comparable to the effect of bromocriptin was shown in the Transwell® assay. Like for bromocriptin, no published data are available investigating the effect of montelukast on BSEP function. But this compound has been reported to induce liver injury in pediatric and adult patients, which cannot be related to bile acid accumulation and hepatic transporter inhibition to date<sup>45,46</sup>. Our study here clearly demonstrates no cis-inhibitory effect of this compound on BSEP in the vesicle-based assay. If added apically in the cell based transflux assay, an inhibitory effect is indeed observed in the basolateral to apical flux of taurocholate. To evaluate whether this effect could be due to the inhibition of the primary step in the transflux assay (the NTCP-mediated uptake of TC), the effect of montelukast was studied in NTCP-expressing CHO cells. Montelukast showed significant inhibition of NTCP-mediated taurocholate uptake, which may explain the effects seen in the Transwell® assay. However, further evaluation is needed to verify this hypothesis.

While we were performing our screening experiments, Morgan and coworkers published a new study on hepatobiliary transport inhibition and its link with liver injury<sup>47</sup>. As part of their study, they measured BSEP inhibition of 600 drugs in a vesicle assay. Among the

1  
2  
3 tested compounds, olmesartan was reported with an  $IC_{50}$  of 4.73  $\mu$ M, pranlukast with an  $IC_{50}$   
4 of 2.97  $\mu$ M, vecuronium with an  $IC_{50}$  over 100  $\mu$ M and zafirlukast with an  $IC_{50}$  of 11.1  $\mu$ M.  
5 These results, apart for vecuronium, are in contradiction with the absence of inhibition at 10  
6  $\mu$ M found in both our vesicle and transcellular transport assays. In our opinion, the most  
7 likely explanation for the discrepancy in the results is of technical nature. In our assay, the  
8 uptake starts by mixing vesicles with the uptake solution containing the substrate, the  
9 inhibitor and ATP. This corresponds to true zero-trans conditions. In contrast, as described in  
10 details by van Staden and co-workers<sup>48</sup>, Morgan *et al.* start the uptake by adding ATP to  
11 vesicles pre-incubated with both substrate and inhibitors. This pre-incubation leads most  
12 likely to a deviation from a true zero-trans condition, which is needed for this type of  
13 transport experiment.  
14

15  
16 All in all, these results point towards the importance of choosing an appropriate  
17 assay system for validating results of *in silico* screens. Ideally, the same method as was used  
18 in the training set of the model should be employed. However, this is not always possible,  
19 especially if diverse data sources are merged together. In general, a model as simple as  
20 possible (a single protein overexpressed, an isolated vesicle, etc.) is recommended to limit  
21 the noise brought by possible other interaction partners. More complex assay systems are of  
22 great help to understand mechanisms and mimic as much as possible *in vivo* effects.  
23  
24

## 25 26 Conclusion

27 In the present work, an *in silico* model based on a large set of compounds has been  
28 developed to identify potential BSEP inhibitors that could induce cholestasis. Best  
29 performance was obtained by RandomForest with embedded feature selection algorithm as  
30 classifier. Subsequent *in silico* screening of DrugBank followed by experimental testing of top  
31 ranked hits allowed the discovery of bromocriptin as previously unknown BSEP inhibitor.  
32

33 In conclusion, this modeling approach allows to quickly flagging compounds with  
34 potential inhibition activity at BSEP that could in theory show drug-induced cholestasis. The  
35 implementation of this model in a KNIME workflow for easy use is a first step for creating a  
36 tool for *in silico* transporter profiling including also the already established models for P-  
37 glycoprotein<sup>49</sup>, the breast cancer protein<sup>37</sup>, as well as ABCC2<sup>14</sup>.  
38  
39

## 40 41 42 Acknowledgement

43 The authors thank the software company ChemAxon for providing us kindly with their  
44 software. The research leading to these results has received support from the Innovative  
45 Medicines Initiative Joint Undertaking under Grant Agreements n° 115002 (eTOX), resources  
46 of which are composed of financial contribution from the European Union's Seventh  
47 Framework Programme (FP7/2007-2013) and EFPIA Companies' in kind contribution. We  
48 acknowledge additional financial support by the Austrian Science Fund (FWF), Grants  
49 F03502, F03509, and F03520. Bruno Stieger is supported by the SNF National Center of  
50 Competence in Research TransCure (University of Berne, Berne, Switzerland).  
51  
52

## 53 54 55 Supporting Information

56 The authors provide as Supplementary Information:

- 57 - the detailed list of the names of the MOE descriptors computed in this study  
58  
59

- an explanation of the software requirement and installation process to run the KNIME workflow
- the characterization of the LLC-PK1 cells
- the Transwell® assay set-up
- the results for NTCP inhibition in NTCP-expressing CHO cells for cyclosporin A, pioglitazone, bromocriptin and montelukast
- the KNIME workflow to run BSEP inhibition predictions using the model described in this study (.zip archive)

This material is available free of charge via the Internet at <http://pubs.acs.org>.

## Bibliography

- (1) Stieger, B. The Role of the Sodium-Taurocholate Cotransporting Polypeptide (NTCP) and of the Bile Salt Export Pump (BSEP) in Physiology and Pathophysiology of Bile Formation. In *Drug Transporters*; Fromm, M. F., Kim, R. B., Eds.; Handbook of Experimental Pharmacology; Springer Berlin Heidelberg, 2011; pp 205–259.
- (2) Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin <http://jpet.aspetjournals.org/content/314/2/876.long> (accessed Jul 1, 2015).
- (3) Strautnieks, S. S.; Bull, L. N.; Knisely, A. S.; Kocoshis, S. A.; Dahl, N.; Arnell, H.; Sokal, E.; Dahan, K.; Childs, S.; Ling, V.; Tanner, M. S.; Kagalwalla, A. F.; Németh, A.; Pawlowska, J.; Baker, A.; Mieli-Vergani, G.; Freimer, N. B.; Gardiner, R. M.; Thompson, R. J. A Gene Encoding a Liver-Specific ABC Transporter Is Mutated in Progressive Familial Intrahepatic Cholestasis. *Nat. Genet.* **1998**, *20* (3), 233–238.
- (4) Fattinger, K.; Funk, C.; Pantze, M.; Weber, C.; Reichen, J.; Stieger, B.; Meier, P. J. The Endothelin Antagonist Bosentan Inhibits the Canalicular Bile Salt Export Pump: A Potential Mechanism for Hepatic Adverse Reactions. *Clin. Pharmacol. Ther.* **2001**, *69* (4), 223–231.
- (5) Funk, C.; Pantze, M.; Jehle, L.; Ponelle, C.; Scheuermann, G.; Lazendic, M.; Gasser, R. Troglitazone-Induced Intrahepatic Cholestasis by an Interference with the Hepatobiliary Export of Bile Acids in Male and Female Rats. Correlation with the Gender Difference in Troglitazone Sulfate Formation and the Inhibition of the Canalicular Bile Salt Export Pump (Bsep) by Troglitazone and Troglitazone Sulfate. *Toxicology* **2001**, *167* (1), 83–98.
- (6) Food and Drug Administration. *Guidance for Industry Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations*; Draft Guidance; U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2012.
- (7) Guideline on the Investigation of Drug Interactions.
- (8) Hirano, H.; Kurata, A.; Onishi, Y.; Sakurai, A.; Saito, H.; Nakagawa, H.; Nagakura, M.; Tarui, S.; Kanamori, Y.; Kitajima, M.; Ishikawa, T. High-Speed Screening and QSAR Analysis of Human ATP-Binding Cassette Transporter ABCB11 (Bile Salt Export Pump) To Predict Drug-Induced Intrahepatic Cholestasis. *Mol. Pharm.* **2006**, *3* (3), 252–265.
- (9) Warner, D. J.; Chen, H.; Cantin, L.-D.; Kenna, J. G.; Stahl, S.; Walker, C. L.; Noeske, T. Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs: Opportunities Provided by Physicochemical Property Modulation, In Silico Modeling, and Structural Modification. *Drug Metab. Dispos.* **2012**, *40* (12), 2332–2341.

- 1  
2  
3 (10) Pedersen, J. M.; Matsson, P.; Bergström, C. A. S.; Hoogstraate, J.; Norén, A.; LeCluyse, E.  
4 L.; Artursson, P. Early Identification of Clinically Relevant Drug Interactions with the  
5 Human Bile Salt Export Pump (BSEP/ABCB11). *Toxicol. Sci. Off. J. Soc. Toxicol.* **2013**, *136*  
6 (2), 328–343.  
7  
8 (11) Fawcett, T. An Introduction to ROC Analysis. *Pattern Recogn Lett* **2006**, *27* (8), 861–874.  
9 (12) Berthold, M. R.; Cebron, N.; Dill, F.; Gabriel, T. R.; Kötter, T.; Meinel, T.; Ohl, P.; Sieb, C.;  
10 Thiel, K.; Wiswedel, B. KNIME: The Konstanz Information Miner. In *Data Analysis,*  
11 *Machine Learning and Applications*; Preisach, C., Burkhardt, P. D. H., Schmidt-Thieme,  
12 P. D. L., Decker, P. D. R., Eds.; Studies in Classification, Data Analysis, and Knowledge  
13 Organization; Springer Berlin Heidelberg, 2008; pp 319–326.  
14 (13) Dawson, S.; Stahl, S.; Paul, N.; Barber, J.; Kenna, J. G. In Vitro Inhibition of the Bile Salt  
15 Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans.  
16 *Drug Metab. Dispos. Biol. Fate Chem.* **2012**, *40* (1), 130–138.  
17 (14) Pinto, M.; Trauner, M.; Ecker, G. F. An In Silico Classification Model for Putative ABCC2  
18 Substrates. *Mol. Inform.* **2012**, *31* (8), 547–553.  
19 (15) Molecular Operating Environment (MOE), 2011.10; Chemical Computing Group Inc.,  
20 1010 Sherbooke St. West, Suite #910, Mont.  
21 (16) Morgan, R. E.; Trauner, M.; van Staden, C. J.; Lee, P. H.; Ramachandran, B.; Eschenberg,  
22 M.; Afshari, C. A.; Qualls, C. W.; Lightfoot-Dunn, R.; Hamadeh, H. K. Interference with  
23 Bile Salt Export Pump Function Is a Susceptibility Factor for Human Liver Injury in Drug  
24 Development. *Toxicol. Sci.* **2010**, *118* (2), 485–500.  
25 (17) Hall, M.; Frank, E.; Holmes, G.; Pfahringer, B.; Reutemann, P.; Witten, I. H. The WEKA  
26 Data Mining Software: An Update. *SIGKDD Explor News* **2009**, *11* (1), 10–18.  
27 (18) Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.;  
28 Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. DrugBank 3.0: A  
29 Comprehensive Resource for “Omics” Research on Drugs. *Nucleic Acids Res.* **2011**, *39*  
30 (Database issue), D1035–D1041.  
31 (19) RDKit <http://www.rdkit.org/> (accessed Jun 16, 2015).  
32 (20) de Waart, D. R.; Häusler, S.; Vlaming, M. L. H.; Kunne, C.; Hänggi, E.; Gruss, H.-J.; Oude  
33 Elferink, R. P. J.; Stieger, B. Hepatic Transport Mechanisms of Cholyl-L-Lysyl-Fluorescein.  
34 *J. Pharmacol. Exp. Ther.* **2010**, *334* (1), 78–86.  
35 (21) Kagawa, T.; Orii, R.; Hirose, S.; Arase, Y.; Shiraiishi, K.; Mizutani, A.; Tsukamoto, H.; Mine,  
36 T. Ursodeoxycholic Acid Stabilizes the Bile Salt Export Pump in the Apical Membrane in  
37 MDCK II Cells. *J. Gastroenterol.* **2014**, *49* (5), 890–899.  
38 (22) Schroeder, A.; Eckhardt, U.; Stieger, B.; Tynes, R.; Schteingart, C. D.; Hofmann, A. F.;  
39 Meier, P. J.; Hagenbuch, B. Substrate Specificity of the Rat Liver Na(+)-Bile Salt  
40 Cotransporter in *Xenopus Laevis* Oocytes and in CHO Cells. *Am. J. Physiol.* **1998**, *274* (2  
41 Pt 1), G370–G375.  
42 (23) Chang, J. H.; Plise, E.; Cheong, J.; Ho, Q.; Lin, M. Evaluating the in Vitro Inhibition of  
43 UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in Predicting Drug-Induced  
44 Hyperbilirubinemia. *Mol. Pharm.* **2013**, *10* (8), 3067–3075.  
45 (24) Brouwer, K. L. R.; Keppler, D.; Hoffmaster, K. A.; Bow, D. a. J.; Cheng, Y.; Lai, Y.; Palm, J.  
46 E.; Stieger, B.; Evers, R.; International Transporter Consortium. In Vitro Methods to  
47 Support Transporter Evaluation in Drug Discovery and Development. *Clin. Pharmacol.*  
48 *Ther.* **2013**, *94* (1), 95–112.  
49 (25) Kubinyi, H. Drug Research: Myths, Hype and Reality. *Nat. Rev. Drug Discov.* **2003**, *2* (8),  
50 665–668.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (26) Kaplowitz, N. Drug-Induced Liver Disorders: Implications for Drug Development and  
4 Regulation. *Drug Saf.* **2001**, *24* (7), 483–490.
- 5 (27) Stieger, B.; Meier, Y.; Meier, P. J. The Bile Salt Export Pump. *Pflüg. Arch. Eur. J.*  
6 *Physiol.* **2007**, *453* (5), 611–620.
- 7 (28) Perez, M.-J.; Briz, O. Bile-Acid-Induced Cell Injury and Protection. *World J.*  
8 *Gastroenterol. WJG* **2009**, *15* (14), 1677–1689.
- 9 (29) Klintmalm, G. B.; Iwatsuki, S.; Starzl, T. E. Cyclosporin A Hepatotoxicity in 66 Renal  
10 Allograft Recipients. *Transplantation* **1981**, *32* (6), 488–489.
- 11 (30) Mason, J. Pharmacology of Cyclosporine (sandimmune). VII. Pathophysiology and  
12 Toxicology of Cyclosporine in Humans and Animals. *Pharmacol. Rev.* **1990**, *41* (3), 423–  
13 434.
- 14 (31) Maeda, K. Hepatocellular Injury in a Patient Receiving Pioglitazone. *Ann. Intern.*  
15 *Med.* **2001**, *135* (4), 306.
- 16 (32) Pinto, A. G.; Cummings, O. W.; Chalasani, N. Severe but Reversible Cholestatic Liver  
17 Injury after Pioglitazone Therapy. *Ann. Intern. Med.* **2002**, *137* (10), 857.
- 18 (33) Chase, M. P.; Yarze, J. C. Pioglitazone-Associated Fulminant Hepatic Failure. *Am. J.*  
19 *Gastroenterol.* **2002**, *97* (2), 502–503.
- 20 (34) Nagasaka, S.; Abe, T.; Kawakami, A.; Kusaka, I.; Nakamura, T.; Ishikawa, S.; Saito, T.;  
21 Ishibashi, S. Pioglitazone-Induced Hepatic Injury in a Patient Previously Receiving  
22 Troglitazone with Success. *Diabet. Med. J. Br. Diabet. Assoc.* **2002**, *19* (4), 347–348.
- 23 (35) May, L. D.; Lefkowitz, J. H.; Kram, M. T.; Rubin, D. E. Mixed Hepatocellular-Cholestatic  
24 Liver Injury after Pioglitazone Therapy. *Ann. Intern. Med.* **2002**, *136* (6), 449–452.
- 25 (36) Bradley, A. P. The Use of the Area under the ROC Curve in the Evaluation of Machine  
26 Learning Algorithms. *Pattern Recognit.* **1997**, *30* (7), 1145–1159.
- 27 (37) Montanari, F.; Ecker, G. F. BCRP Inhibition: From Data Collection to Ligand-Based  
28 Modeling. *Mol. Inform.* **2014**, *33* (5), 322–331.
- 29 (38) Viereck, C.; Boudes, P. An Analysis of the Impact of FDA's Guidelines for Addressing  
30 Cardiovascular Risk of Drugs for Type 2 Diabetes on Clinical Development. *Contemp.*  
31 *Clin. Trials* **2011**, *32* (3), 324–332.
- 32 (39) Hoofnagle, J. H.; Serrano, J.; Knoblen, J. E.; Navarro, V. J. LiverTox: A Website on Drug-  
33 Induced Liver Injury. *Hepatology* **2013**, *57* (3), 873–874.
- 34 (40) Maurer, G.; Schreier, E.; Delaborde, S.; Nufer, R.; Shukla, A. P. Fate and Disposition of  
35 Bromocriptine in Animals and Man. II: Absorption, Elimination and Metabolism. *Eur. J.*  
36 *Drug Metab. Pharmacokinet.* **1983**, *8* (1), 51–62.
- 37 (41) Peyronneau, M.-A.; Delaforge, M.; Riviere, R.; Renaud, J.-P.; Mansuy, D. High Affinity of  
38 Ergopeptides for Cytochromes P450 3A. *Eur. J. Biochem.* **1994**, *223* (3), 947–956.
- 39 (42) Price, P.; Debono, A.; Parkes, J. D.; Marsden, C. D.; Rosenthaler, J. Plasma  
40 Bromocriptine Levels, Clinical and Growth Hormone Responses in Parkinsonism. *Br. J.*  
41 *Clin. Pharmacol.* **1978**, *6* (4), 303–309.
- 42 (43) Kis, E.; Iojá, E.; Nagy, T.; Szente, L.; Herédi-Szabó, K.; Krajcsi, P. Effect of Membrane  
43 Cholesterol on BSEP/Bsep Activity: Species Specificity Studies for Substrates and  
44 Inhibitors. *Drug Metab. Dispos. Biol. Fate Chem.* **2009**, *37* (9), 1878–1886.
- 45 (44) Guyot, C.; Hofstetter, L.; Stieger, B. Differential Effects of Membrane Cholesterol  
46 Content on the Transport Activity of Multidrug Resistance-Associated Protein 2 (ABCC2)  
47 and of the Bile Salt Export Pump (ABCB11). *Mol. Pharmacol.* **2014**, mol.114.092262.
- 48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (45) Lebensztejn, D. M.; Bobrus-Chociej, A.; Kłusek, M.; Uscinowicz, M.; Lotowska, J.;  
4 Sobaniec-Lotowska, M.; Kaczmarski, M. Hepatotoxicity Caused by Montelukast in a  
5 Paediatric Patient. *Przegląd Gastroenterol.* **2014**, *9* (2), 121–123.  
6  
7 (46) Calapai, G.; Casciaro, M.; Miroddi, M.; Calapai, F.; Navarra, M.; Gangemi, S.  
8 Montelukast-Induced Adverse Drug Reactions: A Review of Case Reports in the  
9 Literature. *Pharmacology* **2014**, *94* (1-2), 60–70.  
10 (47) Morgan, R. E.; van Staden, C. J.; Chen, Y.; Kalyanaraman, N.; Kalanzi, J.; Dunn, R. T.;  
11 Afshari, C. A.; Hamadeh, H. K. A Multifactorial Approach to Hepatobiliary Transporter  
12 Assessment Enables Improved Therapeutic Compound Development. *Toxicol. Sci.* **2013**,  
13 *136* (1), 216–241.  
14 (48) van Staden, C. J.; Morgan, R. E.; Ramachandran, B.; Chen, Y.; Lee, P. H.; Hamadeh, H. K.  
15 Membrane Vesicle ABC Transporter Assays for Drug Safety Assessment. In *Current*  
16 *Protocols in Toxicology*; John Wiley & Sons, Inc., 2001.  
17  
18 (49) Klepsch, F.; Vasanthanathan, P.; Ecker, G. F. Ligand and Structure-Based Classification  
19 Models for Prediction of P-Glycoprotein Inhibitors. *J. Chem. Inf. Model.* **2014**, *54* (1),  
20 218–229.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60